These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29885039)

  • 1. Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.
    Wohlfahrt A; Bingham CO; Marder W; Phillips K; Bolster MB; Moreland LW; Zhang Z; Neogi T; Lee YC
    Arthritis Care Res (Hoboken); 2019 Apr; 71(4):521-529. PubMed ID: 29885039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating PROMIS Measures in a Treat-to-Target Approach to Standardize Patient-Centered Treatment of Rheumatoid Arthritis.
    Greene GJ; Beaumont JL; Bacalao EJ; Muftic A; Kaiser K; Eisenstein AR; Mandelin AM; Cella D; Ruderman EM
    J Rheumatol; 2023 Aug; 50(8):1002-1008. PubMed ID: 37127317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study.
    Cohen EM; Edwards RR; Bingham CO; Phillips K; Bolster MB; Moreland LW; Neogi T; Marder W; Wohlfahrt A; Clauw D; Lee YC
    J Clin Rheumatol; 2019 Aug; 25(5):232-236. PubMed ID: 30035754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database.
    Ranganath VK; Paulus HE; Onofrei A; Khanna D; Reed G; Elashoff DA; Kremer JM; Furst DE
    J Rheumatol; 2008 Oct; 35(10):1966-71. PubMed ID: 18785317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.
    Kavanaugh A; Keystone E; Greenberg JD; Reed GW; Griffith JM; Friedman AW; Saunders KC; Ganguli A
    Rheumatology (Oxford); 2017 Jul; 56(7):1095-1101. PubMed ID: 28340006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in physical activity measured by accelerometry following initiation of DMARD therapy in rheumatoid arthritis.
    Prioreschi A; Hodkinson B; Tikly M; McVeigh JA
    Rheumatology (Oxford); 2014 May; 53(5):923-6. PubMed ID: 24459221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
    Dhaon P; Das SK; Srivastava R; Dhakad U
    Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs.
    Radner H; Yoshida K; Frits M; Iannaccone C; Shadick NA; Weinblatt M; Smolen JS; Solomon DH
    Rheumatology (Oxford); 2015 Nov; 54(11):2076-84. PubMed ID: 26163688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis.
    Dewitt EM; Li Y; Curtis JR; Glick HA; Greenberg JD; Anstrom KJ; Kremer JM; Reed G; Schulman KA; Reed SD
    J Rheumatol; 2013 Feb; 40(2):127-36. PubMed ID: 23322461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.
    Ranganath VK; Maranian P; Elashoff DA; Woodworth T; Khanna D; Hahn T; Sarkisian C; Kremer JM; Furst DE; Paulus HE
    Rheumatology (Oxford); 2013 Oct; 52(10):1809-17. PubMed ID: 23813577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry.
    England BR; Yun H; Chen L; Vanderbleek J; Michaud K; Mikuls TR; Curtis JR
    Arthritis Care Res (Hoboken); 2023 Feb; 75(2):231-239. PubMed ID: 34338449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.
    Gavigan K; Nowell WB; Serna MS; Stark JL; Yassine M; Curtis JR
    Arthritis Res Ther; 2020 Jan; 22(1):4. PubMed ID: 31910893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities.
    Bacalao EJ; Greene GJ; Beaumont JL; Eisenstein A; Muftic A; Mandelin AM; Cella D; Ruderman EM
    Clin Rheumatol; 2017 Aug; 36(8):1729-1736. PubMed ID: 28653263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
    Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
    J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
    Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
    Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.
    Curtis JR; Yang S; Chen L; Pope JE; Keystone EC; Haraoui B; Boire G; Thorne JC; Tin D; Hitchon CA; Bingham CO; Bykerk VP
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1345-53. PubMed ID: 25988705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.